Terms: = Liver cancer AND CEBPA, CEBP, 1050, C/EBP-alpha, P49715 AND Prognosis
23 results:
1. Advances in the genetics of nonalcoholic fatty liver disease.
Ajmera V; Loomba R
Curr Opin Gastroenterol; 2023 May; 39(3):150-155. PubMed ID: 37144531
[TBL] [Abstract] [Full Text] [Related]
2. LncRNA cebpa-DT promotes liver cancer metastasis through DDR2/β-catenin activation via interacting with hnRNPC.
Cai Y; Lyu T; Li H; Liu C; Xie K; Xu L; Li W; Liu H; Zhu J; Lyu Y; Feng X; Lan T; Yang J; Wu H
J Exp Clin Cancer Res; 2022 Dec; 41(1):335. PubMed ID: 36471363
[TBL] [Abstract] [Full Text] [Related]
3. Development and validation of a gradient boosting machine to predict prognosis after liver resection for intrahepatic cholangiocarcinoma.
Ji GW; Jiao CY; Xu ZG; Li XC; Wang K; Wang XH
BMC Cancer; 2022 Mar; 22(1):258. PubMed ID: 35277130
[TBL] [Abstract] [Full Text] [Related]
4. Nucleolar protein 6 promotes cell proliferation and acts as a potential novel prognostic marker for hepatocellular carcinoma.
Meng L; Xu KX; Zhao MX; Li K; Zhu K; Yuan DW; Wang HN; Dai PG; Yan R
Chin Med J (Engl); 2021 Sep; 134(21):2611-2618. PubMed ID: 34561331
[TBL] [Abstract] [Full Text] [Related]
5. High-expression of lncRNA cebpa-AS1 promotes liver cancer progression.
Wu C; Tang ZY; Chen HY; Zhang J; Zhao C
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8295-8302. PubMed ID: 31646559
[TBL] [Abstract] [Full Text] [Related]
6. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.
Hamfjord J; Guren TK; Dajani O; Johansen JS; Glimelius B; Sorbye H; Pfeiffer P; Lingjærde OC; Tveit KM; Kure EH; Pallisgaard N; Spindler KG
Ann Oncol; 2019 Jul; 30(7):1088-1095. PubMed ID: 31046124
[TBL] [Abstract] [Full Text] [Related]
7. Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features.
Wang Y; Sun L; Li Z; Gao J; Ge S; Zhang C; Yuan J; Wang X; Li J; Lu Z; Gong J; Lu M; Zhou J; Peng Z; Shen L; Zhang X
Gastric Cancer; 2019 Nov; 22(6):1183-1192. PubMed ID: 30989433
[TBL] [Abstract] [Full Text] [Related]
8. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers.
Wakizaka K; Yokoo H; Kamiyama T; Ohira M; Kato K; Fujii Y; Sugiyama K; Okada N; Ohata T; Nagatsu A; Shimada S; Orimo T; Kamachi H; Taketomi A
J Gastroenterol Hepatol; 2019 Jun; 34(6):1074-1080. PubMed ID: 30462849
[TBL] [Abstract] [Full Text] [Related]
9. Treatment of liver cancer by C/EBPA saRNA.
Zhao X; Voutila J; Ghobrial S; Habib NA; Reebye V
Adv Exp Med Biol; 2017; 983():189-194. PubMed ID: 28639200
[TBL] [Abstract] [Full Text] [Related]
10. 9-bis[2-(pyrrolidin-1-yl)ethoxy]-6-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-11H-indeno[1, 2-c]quinolin-11-one (BPIQ), A Quinoline Derivative Inhibits Human Hepatocellular Carcinoma Cells by Inducing ER Stress and Apoptosis.
Chang WT; Fong Y; Chuang SC; Chou CK; Chou HL; Yang CF; Tseng CH; Chen YL; Chiu CC
Anticancer Agents Med Chem; 2017; 17(5):692-700. PubMed ID: 27491935
[TBL] [Abstract] [Full Text] [Related]
11. Down-Regulation of Nogo-B Expression as a Newly Identified Feature of Intrahepatic Cholangiocarcinoma.
Nanashima A; Hatachi G; Tominaga T; Murakami G; Takagi K; Arai J; Wada H; Nagayasu T; Sumida Y
Tohoku J Exp Med; 2016 Jan; 238(1):9-16. PubMed ID: 26656426
[TBL] [Abstract] [Full Text] [Related]
12. [Treatment of non-cirrhotic, non-tumoural portal vein thrombosis].
Llop E; Seijo S
Gastroenterol Hepatol; 2016; 39(6):403-10. PubMed ID: 26547613
[TBL] [Abstract] [Full Text] [Related]
13. Down-regulation of C/EBP homologous protein (CHOP) expression in gastric cardia adenocarcinoma: Their relationship with clinicopathological parameters and prognostic significance.
Zhu XJ; Gao SG; Li SQ; Shi ZG; Ma ZK; Zhu SS; Feng XS
Clin Res Hepatol Gastroenterol; 2015 Jun; 39(3):391-8. PubMed ID: 25582300
[TBL] [Abstract] [Full Text] [Related]
14. [Expression of β-catenin and HNF-1α and their influence on prognosis in human hepatocellular carcinoma].
Shi J; Yin F
Zhonghua Zhong Liu Za Zhi; 2014 Aug; 36(8):587-91. PubMed ID: 25430024
[TBL] [Abstract] [Full Text] [Related]
15. Antitumor function of microRNA-122 against hepatocellular carcinoma.
Nakao K; Miyaaki H; Ichikawa T
J Gastroenterol; 2014 Apr; 49(4):589-93. PubMed ID: 24531873
[TBL] [Abstract] [Full Text] [Related]
16. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy.
Huo TI; Hsu CY; Huang YH; Su CW; Lin HC; Lee RC; Chiou YY; Chiang JH; Lee PC; Lee SD
BMC Gastroenterol; 2010 Dec; 10():146. PubMed ID: 21194431
[TBL] [Abstract] [Full Text] [Related]
18. [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].
Zhang L; Ren ZG; Gan YH; Wang YH; Zhang BH; Chen Y; Xie XY; Ge NL; Ye SL
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):630-3. PubMed ID: 21122420
[TBL] [Abstract] [Full Text] [Related]
19. Reciprocal expression of CCAAT/enhancer binding proteins alpha and beta in hepatoblastomas and its prognostic significance.
Tomizawa M; Horie H; Yamamoto H; Matsunaga T; Sasaki F; Hashizume K; Hiyama E; Kaneko M; Suita S; Ando H; Hayashi Y; Ohnuma N; Nakagawara A
Oncol Rep; 2007 Feb; 17(2):341-4. PubMed ID: 17203171
[TBL] [Abstract] [Full Text] [Related]
20. Expression of HNFs and C/EBP alpha is correlated with immunocytochemical differentiation of cell lines derived from human hepatocellular carcinomas, hepatoblastomas and immortalized hepatocytes.
Ishiyama T; Kano J; Minami Y; Iijima T; Morishita Y; Noguchi M
Cancer Sci; 2003 Sep; 94(9):757-63. PubMed ID: 12967472
[TBL] [Abstract] [Full Text] [Related]
[Next]
